canakinumab
novartis
['lcsm,(-blcsm)', 'lung', 'nsclc', 'canakinumab', 'canopy-a', 'sclc']
 canopy-a: phase iii study of
canakinumab as adjuvant
therapy in patients with
completely resected non-small cell
lung cancer (nsclc). pan-negative trial - not even improvement on arthralgia vs placebo. #esmo22 #lcsm 
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm